Core Insights - VolitionRx Limited's Nu.Q® NETs H3.1 assay has been included in the DETECSEPS program, aimed at early detection of sepsis, which is a significant public health concern [1][3][5] - The DETECSEPS Consortium has received approximately €6.3 million (~$7.3 million) in funding from the French government as part of the France 2030 plan [1][11] - The program seeks to reduce the socio-economic burden of sepsis, which affects around 166 million people globally and resulted in 21.4 million deaths in 2021 [4][11] Company Overview - VolitionRx is a multi-national epigenetics company focused on developing blood tests for early detection and monitoring of diseases, including sepsis [22][23] - The company aims to operationalize its understanding of epigenetics in clinical practice, particularly through the use of the H3.1 biomarker [9] - Volition's collaboration with Euroimmun will utilize the IDS i10® automated analyzer for routine measurement of H3.1 levels, providing results within one hour [8][9] Industry Context - Sepsis presents a heavy social, economic, and health burden, with significant long-term complications for survivors, including high rates of re-admission and mortality [4][10] - The DETECSEPS program is expected to implement an innovative early screening strategy combining clinical scores and the Nu.Q® H3.1 biomarker, which has shown strong diagnostic performance [5][7] - The potential market for sepsis testing is substantial, with the opportunity representing a multi-billion dollar total addressable market [11]